Author Question: A patient undergoing incentive spirometry should be monitored for outcome by assessing which of the ... (Read 80 times)

jlmhmf

  • Hero Member
  • *****
  • Posts: 552
A patient undergoing incentive spirometry should be monitored for outcome by assessing which of the following?
 
  1. Forced expiratory volume at 1 second (FEV1)
  2. Peak expiratory flow
  3. Partial pressure of arterial oxygen (PaO2)
  4. Blood pressure
  a. 1 and 2 c. 1 and 4
  b. 2 and 3 d. 3 and 4

Question 2

A patient is able to sustain a flow of 900 cc/s to hold the ball of a flow-oriented incentive spi-rometer aloft for 2 seconds. Her inspired volume is ____ L.
 
  a. 0.18 c. 1.45
  b. 0.90 d. 1.80



fur

  • Sr. Member
  • ****
  • Posts: 309
Answer to Question 1

ANS: B
When assessing for outcome from incentive spirometry, the respiratory therapist is looking for the absence of or an improvement in signs of atelectasis. These signs are decreased respiratory rate, resolution of fever, normal pulse rate, improved breath sounds, a normal chest radiograph, im-proved arterial oxygenation, increased vital capacity and peak expiratory flows, return of func-tional residual capacity or vital capacity to preoperative values, and improved inspiratory muscle performance.

Answer to Question 2

ANS: D
Flow = Tidal volume  Inspiratory time.
Tidal volume = Flow  Inspiratory time.
Tidal volume = 900 mL/s  2 s = 1800 mL, or 1.80 L.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

The first successful kidney transplant was performed in 1954 and occurred in Boston. A kidney from an identical twin was transplanted into his dying brother's body and was not rejected because it did not appear foreign to his body.

Did you know?

Blood in the urine can be a sign of a kidney stone, glomerulonephritis, or other kidney problems.

Did you know?

Once thought to have neurofibromatosis, Joseph Merrick (also known as "the elephant man") is now, in retrospect, thought by clinical experts to have had Proteus syndrome. This endocrine disease causes continued and abnormal growth of the bones, muscles, skin, and so on and can become completely debilitating with severe deformities occurring anywhere on the body.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

Patients who have undergone chemotherapy for the treatment of cancer often complain of a lack of mental focus; memory loss; and a general diminution in abilities such as multitasking, attention span, and general mental agility.

For a complete list of videos, visit our video library